The upregulated expression of LYVE1 in tumor tissues indicates tumor-associated lymphangiogenesis and was reported to be associated with worse prognosis in breast cancer, renal cancer, and lung cancer (27–29). Here, LYVE1 is linked to lung carcinoma.